News

Welcome to the news and media section of our website, where we feature corporate news releases and media coverage of interest.

 

Amplimune® Receives US OMRI Listing for Use in Organic Cattle Production

Amplimune®, our immunotherapeutic for calf scours, has received an Organic Materials Review Institute (OMRI) Listing in the U.S.A. This means that Amplimune can be used in compliance with the USDA National Organic Program.

cow's hind leg before and after MCWF treatment

MCWF Shows Promise in Controlling Mycoplasma in Dairy Cattle

NovaVive's MCWF technology has demonstrated potential to control chronic Mycoplasma bovis (M. bovis) infection in dairy cows. M. bovis causes respiratory disease, ear infection, arthritis, mastitis, abortion and other issues.

NovaVive Signs a Co-Operation Agreement with Hoken Biotechnology to Register and Market Amplimune™ in Asia

NovaVive and Hoken Biotechnology have committed to work together to introduce Amplimune™ to Asian markets. Hoken will conduct clinical studies to support regulatory submissions and will be our sales and marketing agent.

cow with calf in field

NovaVive Presents Data Demonstrating Reduction in Antibiotic Use with MCWF in Young Calves

NovaVive today presented a Research Report at the 2017 ACVIM Forum in National Harbor, Maryland. The report summarized the results of a study conducted in a large Canadian veal operation with Amplimune™.

baby calf in a field

Antibiotic Alternative for Cattle Now Available to Canadian Veterinarians

Amplimune™ is now available to Canadian veterinarians. Amplimune is an immunomodulator that reduces the clinical signs/mortality associated with E. coli diarrhea in neonatal calves. It offers an alternative to antibiotics.

Antibiotic Alternative for Cattle Approved for Sale in Canada by the Canadian Food Inspection Agency

Amplimune™ has received approval for sale in Canada by the Canadian Food Inspection Agency. The Company believes this is the first antibiotic alternative therapy for livestock to receive Canadian regulatory approval.

Sign up to stay up-to-date with NovaVive news.